Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer
Open Access
- 5 October 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Abstract
During tumorigenesis, certain tissues are colonized by mutant clones with oncogenic driver mutations as precancer lesions. These mutations can facilitate clonal expansion and may contribute to malignant transformation. The molecular features of low-grade non-muscle invasive bladder cancer (NMIBC) and high-grade bladder cancer are so distinct that they are thought to follow different evolutionary tumorigenesis pathways. Although NMIBC accounts for most bladder tumors, the somatic mutation patterns in “precancer” urothelium of patients with NMIBC remain unclear. Here, we analyzed specimens of normal urothelium and bladder tumors from patients with low-grade and high-grade NMIBC and investigated the genomic evolution of the cancer. Somatic mutations were analyzed using 50 oncogene-targeted sequences and droplet digital polymerase chain reaction for TERT promoter mutations. Somatic mutations in TERT promoter, FGFR3, and CDKN2A were characteristically identified in the normal urothelium of patients with NMIBC. These mutations, consistently identified in both tumor and normal specimens, likely affect clonal expansion during the malignant transformation of NMIBC. Though larger samples and comprehensive study are warranted to confirm our results, the difference in mutational landscape of the precancerous urothelium of patients with bladder cancer could offer deeper understandings of genomic evolution in bladder tumorigenesis.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP 20K18139)
- Young Research Grant from The Japanese Urological Association
- Kobayashi Foundation for Cancer Research
This publication has 40 references indexed in Scilit:
- Highly Recurrent TERT Promoter Mutations in Human MelanomaScience, 2013
- Prognostic Value of Loss of Heterozygosity at Chromosome 9p in Non–muscle-invasive Bladder CancerUrology, 2010
- Molecular pathways of urothelial development and bladder tumorigenesisUrologic Oncology: Seminars and Original Investigations, 2010
- Epigenetic Silencing of the p16 Tumor Suppressor Is Associated with Loss of CTCF Binding and a Chromatin BoundaryMolecular Cell, 2009
- Loss of P16 Expression and Chromosome 9p21 LOH in Predicting Outcome of Patients Affected by Superficial Bladder CancerJournal of Surgical Research, 2007
- TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomesOncogene, 2007
- Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladderInternational Journal of Cancer, 2006
- P16 Immunoreactivity Is an Independent Predictor of Tumor Progression in Minimally Invasive Urothelial Bladder CarcinomaEuropean Urology, 2005
- CDKS and CKIS: Molecular targets for tissue remodellingNature Reviews Drug Discovery, 2002
- A genetic model for colorectal tumorigenesisCell, 1990